Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Q32 Bio Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001661998.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
11/50
Latest evidence
06 Oct 2026
- Public ticker
- QTTB on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
11 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
06 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001661998
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Q32 Bio Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
11/50
Latest evidence
06 Oct 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
39 rows are not safely comparable across share classes.
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
11 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
14%
Boxer Capital Management, LLC
13%
BIOTECHNOLOGY VALUE FUND L P
10%
RA CAPITAL MANAGEMENT, L.P.
9.8%
Frazier Life Sciences Public Fund...
5.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
14%
Reported 13D/G
· 16 Jul 2026
|
$52,590,554
4,127,987 shares
|
— | 30 Jun 2026 |
| Boxer Capital Management, LLC |
13F
13D/G
Company
|
13%
Reported 13D/G
· 30 Jun 2026
|
$40,122,209
3,149,310 shares
|
— | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
Reported 13D/G
· 28 May 2026
|
$13,021,382
2,367,524 shares
|
$0 | 28 May 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.8%
Reported 13D/G
· 28 May 2026
|
$29,715,502
2,332,457 shares
|
— | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.9%
Reported 13D/G
· 02 Oct 2026
|
$19,481,788
1,755,116 shares
|
$0 | 02 Oct 2026 |
| Opaleye Management Inc. |
13D/G
13F
Company
|
5.5%
Reported 13D/G
· 30 Jun 2026
|
$19,904,780
931,000 shares
|
-$6,953,375 | 30 Jun 2026 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
5%
Reported 13D/G
· 30 Jun 2026
|
$25,087,206
1,173,396 shares
|
+$4,588,747 | 30 Jun 2026 |
| Carlyle Group Inc. |
13D/G
13F
The Carlyle Group Inc. · Company
|
4.1%
Reported 13D/G
· 30 Jun 2026
|
$8,321,572
691,735 shares
|
$0 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$59,494,921.
Buys
$60,000,000
Insiders: 4
Sells
$505,079
Insiders: 3
Net
+$59,494,921
Shares: +7,429,662
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,500,000
Shares: 70,338
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 22,054 | $0 | $320,396 | -$320,396 |
| 3-6 | 7,500,000 | 0 | $60,000,000 | $0 | +$60,000,000 |
| 6-9 | 0 | 16,706 | $0 | $75,418 | -$75,418 |
| 9-12 | 0 | 31,578 | $0 | $109,266 | -$109,266 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 33 reporting-owner rows connected to Q32 Bio Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
33
Largest Forms 3/4/5 holder
ORBIMED ADVISORS LLC
Net 12M change
+$59.49M
Full value: +$59,494,920 · USD · 12-month changeLatest report
06 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $6,286,681 | +$15,000,000 | +239% | Mixed | 28 May 2026 |
| Diyong Xu | Director, 10%+ Owner | $5,171,333 | +$15,000,000 | +290% | Mixed | 12 Jun 2026 |
| OrbiMed Capital GP VII LLC | Director, 10%+ Owner | $5,000,000 | +$15,000,000 | +300% | Filing P/S | 28 May 2026 |
| OrbiMed Genesis GP LLC | Director, 10%+ Owner | $5,000,000 | +$15,000,000 | +300% | Filing P/S | 28 May 2026 |
| Atlas Venture Associates Opportunity III, L.P. | Other* | $4,012,500 | Mixed | 26 May 2026 | ||
| Atlas Venture Opportunity Fund Ill, L.P. | Other* | $4,012,500 | Mixed | 26 May 2026 | ||
| Atlas Venture Associates Opportunity III, LLC | Other* | $4,012,500 | Mixed | 26 May 2026 | ||
| W. Bradford Smith | Chief Financial and Business Officer and Treasurer | $2,899,867 | Mixed | 23 Feb 2023 | ||
| Jodie Pope Morrison | CEO, Director | $2,829,048 | -$312,377 | -9.9% | Filing P/S | 06 Oct 2026 |
| Shelia M. Violette | Chief Scientific Officer | $1,517,555 | -$66,672 | -4.2% | Mixed | 06 Oct 2026 |
| Michael L. Blum | Chief Commercial Officer | $1,415,233 | Mixed | 23 Feb 2023 | ||
| Jason Campagna | Chief Medical Officer | $1,221,995 | Mixed | 24 Feb 2025 | ||
| Atlas Venture Fund X, L.P. | 10%+ Owner | $1,194,801 | Mixed | 25 Mar 2024 | ||
| Lee Kalowski | CFO and President | $1,141,226 | -$126,031 | -9.9% | Filing P/S | 06 Oct 2026 |
| Timothy P. Kelly | Chief Operating Officer | $383,965 | Mixed | 24 Feb 2022 | ||
| Isaac Manke | Director | $378,858 | Mixed | 30 Jun 2026 | ||
| Iwicki Mark T. | Director | $342,666 | Mixed | 12 Jun 2026 | ||
| Jeffrey Poulton V | Director | $308,660 | Mixed | 14 Jun 2023 | ||
| Steven Gillis | Director | $308,660 | Mixed | 14 Jun 2023 | ||
| Matthew R. Patterson | Director | $308,660 | Mixed | 14 Jun 2023 |
Recent insider transactions for Q32 Bio Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -0.94% | -$26,798 | $8.32 | -3,221 | 340,038 | 06 Oct 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Sale | -0.72% | -$7,629 | $8.32 | -917 | 126,854 | 06 Oct 2026 | Direct |
| Lee Kalowski | QTTB | Common Stock | Sale | -0.94% | -$10,824 | $8.32 | -1,301 | 137,170 | 06 Oct 2026 | Direct |
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -2.79% | -$163,033 | $16.56 | -9,845 | 343,259 | 25 Aug 2026 | Direct |
| Lee Kalowski | QTTB | Common Stock | Sale | -2.79% | -$65,776 | $16.56 | -3,972 | 138,471 | 25 Aug 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Sale | -2.14% | -$46,335 | $16.56 | -2,798 | 127,771 | 25 Aug 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Award | 40.3% | 37,500 | 130,569 | 16 Jul 2026 | Direct | ||
| Jodie Pope Morrison | QTTB | Common Stock | Award | 59.7% | 132,000 | 353,104 | 16 Jul 2026 | Direct | ||
| Lee Kalowski | QTTB | Common Stock | Award | 59.7% | 53,250 | 142,443 | 16 Jul 2026 | Direct | ||
| Isaac Manke | QTTB | Common Stock | Options Exercise | 53,521 | 53,521 | 30 Jun 2026 | Direct | |||
| Isaac Manke | QTTB | Stock Option (Right to Buy) | Options Exercise | -100% | -53,521 | 0 | 30 Jun 2026 | Direct | ||
| Arthur Tzianabos | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Sven Ante Lundberg | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Kathleen Laporte | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Iwicki Mark T. | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Diyong Xu | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Isaac Manke | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| David S. Grayzel | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Mary Thistle | QTTB | Stock Option (Right to Buy) | Award | 10,826 | 10,826 | 12 Jun 2026 | Direct | |||
| Diyong Xu | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Orbimed Advisors Llc | QTTB | Common Stock | Purchase | 115.2% | $15,000,000 | $8.00 | 1,875,000 | 3,502,987 | 28 May 2026 | See footnotes |
| Lee Kalowski | QTTB | Common Stock | Sale | -10% | -$18,035 | $4.51 | -3,995 | 35,943 | 25 Feb 2026 | Direct |
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -10% | -$44,674 | $4.51 | -9,896 | 89,104 | 25 Feb 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Sale | -4.82% | -$12,708 | $4.51 | -2,815 | 55,569 | 25 Feb 2026 | Direct |
| Shelia M. Violette | QTTB | Common Stock | Award | 67.5% | 37,500 | 93,069 | 24 Feb 2026 | Direct | ||
| Jodie Pope Morrison | QTTB | Common Stock | Award | 148.1% | 132,000 | 221,104 | 24 Feb 2026 | Direct | ||
| Lee Kalowski | QTTB | Common Stock | Award | 148.2% | 53,250 | 89,193 | 24 Feb 2026 | Direct | ||
| David S. Grayzel | QTTB | Stock Option (Right to Buy) | Award | 16,363 | 16,363 | 15 Jan 2026 | Direct | |||
| Sven Ante Lundberg | QTTB | Stock Option (Right to Buy) | Award | 20,363 | 20,363 | 15 Jan 2026 | Direct | |||
| Kathleen Laporte | QTTB | Stock Option (Right to Buy) | Award | 23,272 | 23,272 | 15 Jan 2026 | Direct | |||
| Jodie Pope Morrison | QTTB | Common Stock | Sale | -18.5% | -$77,871 | $3.46 | -22,506 | 99,000 | 02 Dec 2025 | Direct |
| Lee Kalowski | QTTB | Common Stock | Sale | -18.5% | -$31,395 | $3.46 | -9,072 | 39,938 | 02 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.